Registration Now Open for Ingram Micro’s Global ONE Experience – Join Us November 4-5 Online for an Unforgettable Event
7.10.2020 18:30:00 EEST | Business Wire | Press release
For the first time in its history, Ingram Micro Inc. is taking its ONE event to a fully global audience in a completely online interactive experience. Bringing together APAC ONE, EMEA ONE, LATAM ONE and North America ONE enable Ingram Micro to support multiple time zones and languages, while hosting 12 keynotes, 150 sessions and speakers and attendees from more than 60 countries.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201007005717/en/
“We’ve set high expectations, and are excited to have our partners and providers take what they hear, see and experience at ONE and imagine what’s next for their business, their partner ecosystem and their customers." Paul Bay, EVP and President, Global Technology Solutions, Ingram Micro Inc. (Graphic: Business Wire)
As part of the experience, localized content and sessions will be provided for each region. Targeted sessions will also be held pre- and post-experience for special guests attending by countries and communities including Ingram Micro’s SMB Alliance and Trust X Alliance. Ingram Micro channel partners and providers are encouraged to register now at https://imaginenext.ingrammicro.com/one.
Ingram Micro’s executive leadership team will kick off this year’s online experience starting with opening remarks from CEO Alain Monié and EVP and President Paul Bay. Additional event highlights include:
- Fireside chats with Cisco CEO Chuck Robbins and IBM President Jim Whitehurst
- Futurist keynote featuring 311 Institute Founder and CEO Matthew Griffin
- Diversity and Inclusion Keynote from Former NASA Space Science Education Lead Hakeem Oluseyi
- Technology and trends keynote from IDC Group Vice President Michelle Bailey
- Executive addresses from global business leaders including Ingram Micro’s SVP of Marketing Jennifer Anaya, EVP Global Cloud Nimesh Davé, and VP of Global Partner Engagement and IoT Sabine Howest
- Special guests including a GRAMMY award winning musician and bands from around the globe
- An inspired address from one of the best-selling authors, and optimistic motivational speakers on the planet
A complete list of speakers and sessions, including the identities of the above artists and motivational speaker, is noted here. Additionally, several key Ingram Micro announcements and strategic initiatives are expected to launch leading up to and throughout the event, including community announcements from SMB Alliance and Trust X Alliance. Live networking, virtual happy hours and AI-powered business matchups are also on tap for attendees.
“We’ve set high expectations, and are excited to have our partners and providers take what they hear, see and experience at ONE and imagine what’s next for their business, their partner ecosystem and their customers,” said Bay. “Together we are working smarter, harder and with a greater purpose. Ingram Micro and the ecosystem of partner excellence we support has never been more relevant to the vitality and success of today’s business landscape locally, regionally and globally…and we’re ready to do even more.”
Channel press and analysts are welcome to register and attend designated sessions of the Nov. 4-5 Ingram Micro ONE Experience.
For more information visit https://imaginenext.ingrammicro.com/one.
About Ingram Micro
Ingram Micro helps businesses realize the promise of technology. It delivers a full spectrum of global technology and supply chain services to businesses around the world. Deep expertise in technology solutions, mobility, cloud, and supply chain solutions enables its business partners to operate efficiently and successfully in the markets they serve. Unrivaled agility, deep market insights and the trust and dependability that come from decades of proven relationships, set Ingram Micro apart and ahead. Discover how Ingram Micro can help you realize the promise of technology. More at www.ingrammicro.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201007005717/en/
Contact information
Marie Rourke
WhiteFox Marketing
714.292.2199
marie@whitefoxpr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom